Supported by the National Natural Science Foundation of China (T2225006, T2425021) and other programs, Professor Mo Li from Peking University, Professor Lingqian Chang from Beihang University, Professor Cunjiang Yu from the University of Illinois at Urbana-Champaign, and Professor Xinge Yu from City University of Hong Kong have collaborated to develop a novel molecular delivery technology, NanoFLUID, for multiple internal organs. Their research introduces a new strategy for targeted therapy of major diseases such as solid tumors. The research article, entitled “A battery-free nanofluidic intracellular delivery patch for internal organs”, was published in Nature on April 30, 2025.

In the field of disease treatment, achieving precise and targeted delivery of drugs, genes, or therapeutic molecules to specific organs remains a major challenge in medicine and engineering. Existing delivery systems must overcome multiple physiological barriers, including selective vascular permeability, heterogeneity of organ-specific microenvironments, and the biophysical constraints of the cell membrane. To address these challenges, the researchers developed the NanoFLUID patch, which adheres seamlessly to the surface of internal organs, such as the liver and mammary gland, enabling highly customized targeted delivery. By leveraging a gene library co-transfection strategy mediated by NanoFLUID, the researchers performed in vivo screening and identified DUS2 as a key driver of breast cancer metastasis. Further experiments in mouse models demonstrated that targeted inhibition of DUS2 effectively suppressed distant metastasis of breast cancer. These findings provide a new framework for elucidating the molecular mechanisms underlying major diseases and for developing precise organ-targeted therapeutic strategies.

Figure. NanoFLUID patch and its application in targeted tumor therapy